Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1NET 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Uveal Melanoma 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Breast Neoplasms 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma of Lung 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interleukin-13 × Endocrine × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡